-
EP3679063
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3679063
| EP3679063 - COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 29.04.2022 Database last updated on 31.08.2024 | |
| Former | Request for examination was made Status updated on 12.06.2020 | ||
| Former | The international publication has been made Status updated on 16.03.2019 | Most recent event Tooltip | 29.04.2022 | Application deemed to be withdrawn | published on 01.06.2022 [2022/22] | Applicant(s) | For all designated states The Regents of The University of Colorado, A Body Corporate 1800 Grant Street, 8th Floor Denver, CO 80203 / US | [2020/29] | Inventor(s) | 01 /
DOEBELE, Robert C. 752 S. Williams Street Denver Colorado 80209 / US | [2020/29] | Representative(s) | Forresters IP LLP Skygarden Erika-Mann-Straße 11 80636 München / DE | [N/P] |
| Former [2020/29] | Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB | Application number, filing date | 18853161.0 | 07.09.2018 | [2020/29] | WO2018US49842 | Priority number, date | US201762556121P | 08.09.2017 Original published format: US 201762556121 P | US201862712531P | 31.07.2018 Original published format: US 201862712531 P | [2020/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019051155 | Date: | 14.03.2019 | Language: | EN | [2019/11] | Type: | A1 Application with search report | No.: | EP3679063 | Date: | 15.07.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.03.2019 takes the place of the publication of the European patent application. | [2020/29] | Search report(s) | International search report - published on: | US | 14.03.2019 | (Supplementary) European search report - dispatched on: | EP | 30.04.2021 | Classification | IPC: | A61K31/519, C07K14/71, A61K31/517, A61P35/00 | [2021/22] | CPC: |
A61K45/06 (EP,KR,US);
A61K31/519 (EP,KR,US);
A61P35/00 (EP,KR,US);
C07K14/71 (EP);
C12Q1/6886 (KR);
C12Q2600/106 (KR);
C12Q2600/156 (KR)
(-)
|
| Former IPC [2020/29] | C07K14/71, A61K31/519, A61K31/517 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/29] | Title | German: | VERBINDUNGEN, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG ODER VORBEUGUNG VON HER-GESTEUERTEM ARZNEIMITTELRESISTENTEM KREBS | [2020/29] | English: | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | [2020/29] | French: | COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT OU DE PRÉVENTION DE CANCERS PHARMACORÉSISTANTS INDUITS PAR HER | [2020/29] | Entry into regional phase | 07.04.2020 | National basic fee paid | 07.04.2020 | Search fee paid | 07.04.2020 | Designation fee(s) paid | 07.04.2020 | Examination fee paid | Examination procedure | 07.04.2020 | Examination requested [2020/29] | 29.10.2020 | Amendment by applicant (claims and/or description) | 30.11.2021 | Application deemed to be withdrawn, date of legal effect [2022/22] | 14.01.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2022/22] | Fees paid | Renewal fee | 28.09.2020 | Renewal fee patent year 03 | 27.09.2021 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2016090174 (AUCKLAND UNISERVICES LTD [NZ], et al) [A] 1-15* [0007], [0008] *; | [IP] - ESTRADA-BERNAL ADRIANA ET AL, "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions", EGFR/HER2, (20180101), doi:10.1158/1535-7163.TARG-17-A157, pages A157 - A157, XP055792465 [IP] 2-7,9-15 * whole document, in particular Fig. 2,3 and 5 * DOI: http://dx.doi.org/10.1158/1535-7163.TARG-17-A157 | International search | [Y]US2012202832 (SMAILL JEFFREY BRUCE [NZ], et al) [Y] 1-8* . Especially para [0037], [0042], [0170], [0172], [0334], sheet 2 fig 2, sheet 4 fig 4. *; | [Y] - ELAMIN et al., "Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC", J Thor Oncol, (20170800), vol. 20, no. 8, page 1536, XP055581075 [Y] 1-8 * . Especially abstract. * DOI: http://dx.doi.org/10.1016/j.jtho.2017.06.020 | [Y] - SHROTRIYA, "Safe Harbor Statement", Spectrum Pharmaceuticals, (20170100), pages 1 - 28, URL: https://www.sec.gov/Archives/edgar/data/831547/000083154717000002/sppicorporatepresentaf74.htm, (20181031), XP055581082 [Y] 1-8 * . Especially PDF pg 3. * |